Edgar Filing: ALLERGAN INC - Form 4

ALLERGAN IN Form 4	ΙC									
October 05, 200	5									
FORM 4	1		OF OU			GHANGE			PPROVAL	
	UNITED	STATES		RITIES A			COMMISSIO	N OMB Number:	3235-0287	
Check this bo if no longer subject to Section 16. Form 4 or Form 5 obligations	STATEN Filed put	MENT OF	Section 1	SECUI	Estimated burden hou response	urs per				
may continue See Instructio 1(b).				•	•	npany Act ny Act of 1	of 1935 or Sect 940	ion		
(Print or Type Resp	onses)									
1. Name and Address of Reporting Person <u>*</u> EVANS HANDEL			2. Issuer Name and Ticker or Trading Symbol ALLERGAN INC [(AGN)]				5. Relationship of Reporting Person(s) to Issuer			
						1)]	(Check all applicable)			
(Last) (First) (Middle) 2525 DUPONT DRIVE			3. Date of Earliest Transaction (Month/Day/Year) 10/03/2005				X_ Director 10% Owner Officer (give title Other (specify below) below)			
	4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 						
IRVINE, CA 9	2612						Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	le I - Non-	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
	`ransaction Date onth/Day/Year)	2A. Deema Execution any (Month/Da	Date, if	Code (Instr. 8)	4. Securit nAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D) 4 and 5) (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report o	on a separate line	e for each cl	ass of sec	urities bene	Perso inforn requir	ns who rest nation cont red to resp nys a curre	or indirectly. spond to the collect tained in this forr ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number	6. Date Exercisable and	7. Title and Amount of	8. Pric
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transactio	onof Derivative	Expiration Date	Underlying Securities	Deriva
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	Securi
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired			(Instr.

Edgar Filing: ALLERGAN INC - Form 4

	Derivative Security				(A) or Dispose (D) (Instr. 3 and 5)						
			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Phantom Stock Units	<u>(1)</u>	10/03/2005	А		82.83 (2)		(3)	(3)	Common Stock	0	\$ 90
Phantom Stock Units	<u>(1)</u>	10/03/2005	А		27.61 (2)		(3)	(3)	Common Stock	0	\$ 90

Reporting Owners

Reporting Owner Name / Address		Relationsh	ips				
1	Director	10% Owner	Officer	Other			
EVANS HANDEL 2525 DUPONT DRIVE IRVINE, CA 92612	Х						
Signatures							
By: Matthew J. Maletta, Attorney-in-Fact		10/05	/2005				
**Signature of Reporting Person		Da	te				
Explanation of Responses:							

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Converts to common stock on a 1-for-1 basis.
- (2) Phantom stock units acquired under the Allergan, Inc. Deferred Directors' Fee Program in lieu of cash for quarterly portion of annual retainer.
- (3) Phantom stock units are to be settled 100% in stock upon the reporting person's retirement as an Allergan, Inc. director.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.